Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 8/20 | 0.35 |
| ▸ | MMP3 | P08254 | 8/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023970 | 0.86 | ACE (0.68) | ACESMN1; SMN2 | |
| SCHEMBL10951566 | 0.86 | ACE (0.68) | ACEMMP1MMP3 | |
| SCHEMBL11025138 | 0.79 | ACE (0.90) | ACE | |
| SCHEMBL11284829 | 0.78 | ALDH1A1 (0.37) | ACESMN1; SMN2MMP1MMP3EPHX2 | |
| SCHEMBL10956427 | 0.77 | ACE (0.92) | ACE | |
| SCHEMBL12525641 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2MMP1MMP3EPHX2ALDH1A1 | |
| SCHEMBL12494329 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2MMP1MMP3EPHX2ALDH1A1 | |
| SCHEMBL11026370 | 0.74 | ACE (0.68) | ACEMMP1MMP3 | |
| SCHEMBL17662280 | 0.69 | KMT2A (0.48) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL11023967 | 0.69 | ACE (0.90) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0049842-B1 | SUBSTITUTED ENANTHOLACTAM DERIVATIVES, A PROCESS FOR THE PREPARATION AND A PHARMACEUTICAL COMPOSITION USEFUL IN THE TREATMENT OF HYPERTENSION COMPRISING THE SAME, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0049842-A2 | Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-21 | — | — | EP | disclosed |